Sebastian Stintzing
About
Sebastian Stintzing is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Sebastian Stintzing has authored 328 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 261 papers in Oncology, 140 papers in Pulmonary and Respiratory Medicine and 75 papers in Pathology and Forensic Medicine. Recurrent topics in Sebastian Stintzing's work include Colorectal Cancer Treatments and Studies (220 papers), Gastric Cancer Management and Outcomes (70 papers) and Genetic factors in colorectal cancer (70 papers). Sebastian Stintzing is often cited by papers focused on Colorectal Cancer Treatments and Studies (220 papers), Gastric Cancer Management and Outcomes (70 papers) and Genetic factors in colorectal cancer (70 papers). Sebastian Stintzing collaborates with scholars based in Germany, United States and Austria. Sebastian Stintzing's co-authors include Volker Heinemann, Dominik Paul Modest, Heinz‐Josef Lenz, Andreas Jung, Thomas Kirchner, Ludwig Fischer von Weikersthal, Julian Walter Holch, Ingrid Ricard, Clemens Gießen and Ursula Vehling‐Kaiser and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Sebastian Stintzing
298 papers receiving 5.9k citations
Hit Papers
Peers
Sebastian Stintzing
Michael Schlichting Germany
Chiara Cremolini Italy
Alain Hendlisz Belgium
István Láng Hungary
Filippo Pietrantonio Italy
Bruce J. Giantonio United States
Tae‐You Kim South Korea
Rona Yaeger United States
Vladimir Moiseyenko Russia
Anthony B. El-Khoueiry United States
Citations per year, relative to Sebastian Stintzing Sebastian Stintzing (= 1×)
peers
Michael Schlichting
Countries citing papers authored by Sebastian Stintzing
Since
Specialization
Citations
This map shows the geographic impact of Sebastian Stintzing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sebastian Stintzing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sebastian Stintzing more than expected).
Fields of papers citing papers by Sebastian Stintzing
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sebastian Stintzing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sebastian Stintzing. The network helps show where Sebastian Stintzing may publish in the future.
Co-authorship network of co-authors of Sebastian Stintzing
This figure shows the co-authorship network connecting the top 25 collaborators of Sebastian Stintzing. A scholar is included among the top collaborators of Sebastian Stintzing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sebastian Stintzing. Sebastian Stintzing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Stintzing, Sebastian, Richard Greil, Jens Kisro, et al.. (2025). 40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC. Annals of Oncology. 36. S25–S25.
2.
Stahler, Arndt, Dominik Paul Modest, Sebastian Stintzing, et al.. (2024). Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of RAS wild-type (WT) metastatic colorectal cancer (mCRC): Pooled analysis of the randomized trials FIRE-1, FIRE-3, XELAVIRI, and PanaMa.. Journal of Clinical Oncology. 42(16_suppl). 3529–3529.
3.
Pecher, Gabriele, et al.. (2024). Next generation CD44v6-specific CAR-NK cells for the treatment of solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e14518–e14518.
4.
Stahler, Arndt, Christine Sers, Soulafa Mamlouk, et al.. (2024). Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212). Clinical Cancer Research. 30(7). 1256–1263.
5.
Cremolini, Chiara, Clara Montagut, Philippe Ronga, et al.. (2023). Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Frontiers in Oncology. 12. 946850–946850.
6.
Neumann, Christopher, F Schneider, Georg Hilfenhaus, et al.. (2023). Impact of Smoking, Body Weight, Diabetes, Hypertension and Kidney Dysfunction on Survival in Pancreatic Cancer Patients—A Single Center Analysis of 2323 Patients within the Last Decade. Journal of Clinical Medicine. 12(11). 3656–3656.
7.
Gallois, Claire, Édouard Auclin, Elisabeth Bergen, et al.. (2023). 625P Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study. Annals of Oncology. 34. S446–S446.
8.
Uluk, Deniz, Isabella Lurje, Cornelius Engelmann, et al.. (2022). Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers. 14(4). 1026–1026.
9.
Ocker, Matthias, Christian Mayr, Sebastian Stintzing, et al.. (2022). Ferroptosis in Hepatocellular Carcinoma: Mechanisms, Drug Targets and Approaches to Clinical Translation. Cancers. 14(7). 1826–1826.
10.
Arai, Hiroyuki, Shu Cao, Francesca Battaglin, et al.. (2021). RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. Molecular Cancer Therapeutics. 20(6). 1153–1160.
11.
Stahler, Arndt, Volker Heinemann, Kathrin Heinrich, et al.. (2021). Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). European Journal of Cancer. 157. 71–80.
12.
Stahler, Arndt, Sebastian Stintzing, Dominik Paul Modest, et al.. (2020). Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. Clinical Cancer Research. 26(24). 6559–6567.
13.
Laurent‐Puig, Pierre, Volker Heinemann, Daniel Neureiter, et al.. (2018). Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research. 25(1). 134–141.
14.
Berger, Martin D., Sebastian Stintzing, Volker Heinemann, et al.. (2017). A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clinical Cancer Research. 24(4). 784–793.
15.
Matsusaka, Satoshi, Diana L. Hanna, Shu Cao, et al.. (2016). Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clinical Cancer Research. 22(13). 3218–3226.
16.
Stintzing, Sebastian, Wu Zhang, Volker Heinemann, et al.. (2015). Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. Molecular Cancer Therapeutics. 14(10). 2374–2381.
17.
Gießen, Clemens, Ruediger P. Laubender, Donna P. Ankerst, et al.. (2014). Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials. Acta Oncologica. 54(2). 187–193.
18.
Wakatsuki, Takeru, Melissa J. LaBonte, Pierre Bohanes, et al.. (2013). Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics. 12(10). 2261–2272.
19.
Ning, Yan, Armin Gerger, Wu Zhang, et al.. (2013). Plastin Polymorphisms Predict Gender- and Stage-Specific Colon Cancer Recurrence after Adjuvant Chemotherapy. Molecular Cancer Therapeutics. 13(2). 528–539.
20.
Gießen, Clemens, Ruediger P. Laubender, Donna P. Ankerst, et al.. (2012). Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials. Clinical Cancer Research. 19(1). 225–235.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michael Schlichting Breakdown of academic impact, for papers by Chiara Cremolini Breakdown of academic impact, for papers by Alain Hendlisz Breakdown of academic impact, for papers by István Láng Breakdown of academic impact, for papers by Filippo Pietrantonio Breakdown of academic impact, for papers by Bruce J. Giantonio Breakdown of academic impact, for papers by Tae‐You Kim Breakdown of academic impact, for papers by Rona Yaeger Breakdown of academic impact, for papers by Vladimir Moiseyenko Breakdown of academic impact, for papers by Anthony B. El-Khoueiry